Development of a dose-response model for SARS coronavirus
- PMID: 20497390
- PMCID: PMC7169223
- DOI: 10.1111/j.1539-6924.2010.01427.x
Development of a dose-response model for SARS coronavirus
Abstract
In order to develop a dose-response model for SARS coronavirus (SARS-CoV), the pooled data sets for infection of transgenic mice susceptible to SARS-CoV and infection of mice with murine hepatitis virus strain 1, which may be a clinically relevant model of SARS, were fit to beta-Poisson and exponential models with the maximum likelihood method. The exponential model (k= 4.1 x l0(2)) could describe the dose-response relationship of the pooled data sets. The beta-Poisson model did not provide a statistically significant improvement in fit. With the exponential model, the infectivity of SARS-CoV was calculated and compared with those of other coronaviruses. The does of SARS-CoV corresponding to 10% and 50% responses (illness) were estimated at 43 and 280 PFU, respectively. Its estimated infectivity was comparable to that of HCoV-229E, known as an agent of human common cold, and also similar to those of some animal coronaviruses belonging to the same genetic group. Moreover, the exponential model was applied to the analysis of the epidemiological data of SARS outbreak that occurred at an apartment complex in Hong Kong in 2003. The estimated dose of SARS-CoV for apartment residents during the outbreak, which was back-calculated from the reported number of cases, ranged from 16 to 160 PFU/person, depending on the floor. The exponential model developed here is the sole dose-response model for SARS-CoV at the present and would enable us to understand the possibility for reemergence of SARS.
Figures
Similar articles
-
SARS-related virus predating SARS outbreak, Hong Kong.Emerg Infect Dis. 2004 Feb;10(2):176-8. doi: 10.3201/eid1002.030533. Emerg Infect Dis. 2004. PMID: 15030679 Free PMC article.
-
SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview.Infez Med. 2020 Ahead Of Print Jun 1;28(2):174-184. Infez Med. 2020. PMID: 32275259 Review.
-
Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome.Lancet. 2004 Jan 10;363(9403):99-104. doi: 10.1016/s0140-6736(03)15259-2. Lancet. 2004. PMID: 14726162 Free PMC article.
-
A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV.Virol Sin. 2020 Jun;35(3):290-304. doi: 10.1007/s12250-020-00252-z. Epub 2020 Jun 30. Virol Sin. 2020. PMID: 32607866 Free PMC article. Review.
-
Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19.Infez Med. 2020 Jun 1;28(suppl 1):6-17. Infez Med. 2020. PMID: 32532933 Review.
Cited by
-
Breathing, speaking, coughing or sneezing: What drives transmission of SARS-CoV-2?J Intern Med. 2021 Nov;290(5):1010-1027. doi: 10.1111/joim.13326. Epub 2021 Jun 8. J Intern Med. 2021. PMID: 34105202 Free PMC article. Review.
-
Existence of SARS-CoV-2 RNA on ambient particulate matter samples: A nationwide study in Turkey.Sci Total Environ. 2021 Oct 1;789:147976. doi: 10.1016/j.scitotenv.2021.147976. Epub 2021 May 25. Sci Total Environ. 2021. PMID: 34058581 Free PMC article.
-
Face masks effectively limit the probability of SARS-CoV-2 transmission.Science. 2021 May 20;372(6549):1439-43. doi: 10.1126/science.abg6296. Online ahead of print. Science. 2021. PMID: 34016743 Free PMC article.
-
Secondary transmission of SARS-CoV-2 through wastewater: Concerns and tactics for treatment to effectively control the pandemic.J Environ Manage. 2021 Jul 15;290:112668. doi: 10.1016/j.jenvman.2021.112668. Epub 2021 Apr 19. J Environ Manage. 2021. PMID: 33895445 Free PMC article. Review.
-
SARS-CoV-2 and other airborne respiratory viruses in outdoor aerosols in three Swiss cities before and during the first wave of the COVID-19 pandemic.Environ Int. 2022 Jun;164:107266. doi: 10.1016/j.envint.2022.107266. Epub 2022 Apr 29. Environ Int. 2022. PMID: 35512527 Free PMC article.
References
-
- World Health Organization . Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available at: http://www.who.int/csr/sars/country/table2004_04_21/en/index.html, Accessed on August 17, 2008.
-
- Rockx B, Baric RS. Grand challenges in human coronavirus vaccine development In Thiel V. (ed). Coronaviruses, Molecular and Cellular Biology. Norfolk, UK : Caister Academic Press, 2007.
-
- Keyaerts E, Vijgen L, Ranst MV. Current status of antiviral severe acute respiratory syndrome coronavirus research In Thiel V. (ed). Coronaviruses, Molecular and Cellular Biology. Norfolk, UK : Caister Academic Press, 2007.
-
- Dye C, Gay N. Modeling the SARS epidemic. Science, 2003; 300:1884–1885. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous